This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant Neoplasm of Heart, Mediastinum and Pleura심장·종격동·흉막의 악성신생물 (종격동암)

📋 Contents and key points
A. Classification codesICD-10 C38 (C38.0 heart, C38.1 anterior mediastinum, C38.2 posterior mediastinum, C38.3 mediastinum, unspecified, C38.4 pleura, C38.8 overlapping lesion)
B. SynonymsMediastinal cancer, primary cardiac tumor, malignant pleural tumor, pleural mesothelioma (mesothelioma is classified separately under C45), mediastinal lymphoma, cardiac sarcoma
C. Adult onsetVery high — occurs mainly in adults; cardiac tumors can occur at any age
Special Copayment ReductionV193 · 5 years from the cancer patient registration date · 5% copayment
1. HistoryHistory of mediastinal anatomy; recognition of the rarity of primary cardiac tumors; history of research on the association between pleural tumors and asbestos
2. CausesAsbestos (pleural malignancy), radiation, mediastinal lymphoma (EBV-associated), cardiac sarcoma of unknown cause
3. GeneticsNF2, BAP1 (pleura); TP53, RB1 (cardiac sarcoma); lymphoma: MYC, BCL2, BCL6 rearrangements
4. EpidemiologyVery rare tumors; primary cardiac malignancies account for 25% of all cardiac tumors; mediastinal tumors include diverse histologic types
5. PathophysiologyAsbestos fibers → chronic pleural inflammation → mesothelial cell transformation; multistep carcinogenesis of cardiac sarcoma; B-cell transformation in lymphoma
6. SymptomsPericardial effusion, arrhythmia, heart failure symptoms (heart); chest pain, dyspnea, pleural effusion (pleura); SVC syndrome (mediastinum)
7. SignsDiminished heart sounds, pericardial friction rub (heart); pleural friction rub, dullness to chest percussion (pleura); jugular venous distension (SVC)
8. ScreeningNo standard screening test; regular chest imaging recommended for people exposed to asbestos; regular checkups for immunocompromised patients
9. DiagnosisChest CT/MRI/PET-CT; echocardiography; tissue biopsy (mediastinoscopy, VATS, pericardiocentesis); immunohistochemistry
10. TreatmentSurgery (when resectable), radiation, chemotherapy (by histologic type); R-CHOP for lymphoma; ipaxarep for cardiac sarcoma
11. PrognosisHighly variable by histologic type; median survival of primary cardiac sarcoma 6–12 months; lymphoma relatively favorable
12. PreventionAvoidance of asbestos exposure, minimization of radiation exposure, HIV prevention and treatment, infection control in immunocompromised patients
13. ReferencesInternational literature on ICD-10 C38, thoracic surgery textbooks, NCCN guidelines, cardio-oncology literature

1. History

The malignant neoplasms of the heart, mediastinum, and pleura covered by ICD-10 code C38 form a clinically very heterogeneous group of tumors. Because of their rarity and anatomic complexity, tumors in this region have historically posed many difficulties in diagnosis and treatment.

The history of mediastinal tumors began with the development of thoracic surgery in the late 19th century. Initially, most mediastinal tumors were found incidentally at autopsy, and diagnosis in living patients became possible in the early 20th century with the introduction of chest X-rays. Advances in thoracic surgical techniques in the 1920s–1930s made access to the mediastinum possible, and systematic classification of mediastinal tumors began after the 1950s–1960s.

Primary cardiac tumors are very rare and were first systematically described by Cruveilhier in 1854. Most cardiac tumors are benign (about 75% of all), and myxoma is the most common among them. Malignant primary cardiac tumors account for about 25% of all cardiac tumors, and angiosarcoma is the most common primary cardiac malignancy.

Research on the association between pleural malignancies and asbestos gained momentum in the 1960s, when Irving Selikoff and colleagues showed a sharp rise in mesothelioma incidence in a cohort study of asbestos workers. This later became the epidemiologic basis for asbestos regulation and for recognizing mesothelioma as an occupational disease. Pleural malignancies include metastatic pleural tumors and primary pleural sarcomas, excluding mesothelioma (C45).

2. Causes

The various tumors included in the C38 category each have different causative factors.

Pleural malignancies

Asbestos is the most important cause of pleural malignancy; crocidolite (blue asbestos) and amosite (brown asbestos) are the most carcinogenic. Asbestos fibers penetrate deep into the lungs through respiration, reach the pleura, and induce malignant transformation through a chronic inflammatory response lasting decades. The latency period is very long, generally 30–40 years. Radiation exposure is also known to increase the risk of pleural malignancy.

Mediastinal malignancies

Tumors of various histologic types can arise in the mediastinum. Mediastinal large B-cell lymphoma (PMBCL) originates from thymic B cells and is relatively common in young women. Hodgkin lymphoma frequently arises in the anterior mediastinum, and an association with EBV has been reported. Germ cell tumors and neurogenic tumors also arise in the mediastinum. Radiation exposure (prior mediastinal radiotherapy) increases the risk of secondary mediastinal malignancies.

Primary cardiac malignancies

The cause of most primary cardiac sarcomas is unknown. Radiation exposure is known to act as a risk factor in some cases, and the risk may be increased in immunosuppressed patients (especially HIV/AIDS and after organ transplantation). Regarding genetic predisposition, cardiac sarcoma has been reported as part of soft tissue sarcomas in patients with Li-Fraumeni syndrome (TP53 germline variants).

3. Genetics

The genomic characteristics of tumors within the C38 category differ greatly by histologic type.

Pleural malignancies

In primary malignant mesothelioma of the pleura (classified under C45 but pathologically related), characteristic key gene alterations are biallelic inactivation of NF2 (neurofibromatosis type 2) (about 40–50%), BAP1 (BRCA1-associated protein-1) variants (about 60%), and CDKN2A (p16) deletion (about 70–80%). Data on specific gene alterations in primary pleural sarcoma are limited.

Mediastinal lymphoma

Primary mediastinal large B-cell lymphoma (PMBCL) is characterized by activation of the JAK2/STAT6 pathway, MYC and BCL2 amplification, and PD-L1 (CD274) overexpression. PD-L1 overexpression can be a therapeutic target for immune checkpoint inhibitors (pembrolizumab). In classical Hodgkin lymphoma, abnormalities of the JAK-STAT and NF-κB signaling pathways in HRS (Hodgkin Reed-Sternberg) cells are central.

Primary cardiac sarcoma

In cardiac angiosarcoma, variants of the KDR (VEGFR2), PTPRB, and PLCG1 genes have been reported. In cardiac undifferentiated pleomorphic sarcoma, TP53 and RB1 variants are common, and liposarcoma with MDM2 amplification also rarely arises in the heart. Overall, cardiac sarcomas tend to show a complex karyotype.

4. General epidemiology

All tumors included in C38 are very rare. The incidence of primary cardiac tumors is extremely low at 0.001–0.03% of all autopsy cases, of which malignant tumors account for about 25%. Angiosarcoma is the most common primary cardiac malignancy (about 37%) and mainly originates in the right atrium. The annual incidence of primary cardiac tumors is estimated at about 1.38 per 1 million people.

The types of mediastinal malignancies differ by anatomic compartment. Thymoma (C37), lymphoma, and germ cell tumors mainly arise in the anterior mediastinum; bronchogenic cysts and lymphoma in the middle mediastinum; and neurogenic tumors are common in the posterior mediastinum. Specific statistics on the incidence of mediastinal malignancies are limited, but they are estimated to account for less than 1% of all malignancies.

Among pleural malignancies, metastatic lesions are far more common, and primary pleural malignancies (excluding mesothelioma) are very rare. The risk is high in people exposed to asbestos, those with a history of radiotherapy, and immunocompromised patients. In Korea, pleural malignancies due to past exposure continue to occur even after the total asbestos ban in 2009.

5. Pathophysiology

Pleural malignancies

The pathogenesis of pleural malignancies is mainly due to the physical and chemical actions of asbestos fibers. Asbestos fibers reach the pleura via the alveoli and cause repeated mechanical injury and a chronic inflammatory response. As excessive production of reactive oxygen species (ROS), DNA damage, and inhibition of apoptosis persist, genetic alterations accumulate in pleural mesothelial or stromal cells. Along with inactivation of tumor suppressor genes such as NF2 and BAP1, activation of the PI3K-AKT-mTOR and RAS-MAPK pathways contributes to malignant transformation.

Primary cardiac sarcoma

The exact pathogenesis of cardiac sarcoma is unclear. It is presumed to arise from mesenchymal progenitor cells in the heart through a multistep carcinogenic process. In angiosarcoma, abnormalities of VEGFR and related pathways in vascular endothelial cells play an important role. Prior radiotherapy acts as a risk factor for secondary cardiac sarcoma, in which case TP53 variants and complex karyotypic abnormalities are observed.

Mediastinal lymphoma

Primary mediastinal large B-cell lymphoma (PMBCL) originates from B cells of the thymic medulla, and its key pathogenic mechanisms are constitutive activation of the STAT6 pathway due to JAK2 amplification and abnormal IL-13 stimulatory signaling. Sustained activation of the NF-κB pathway also contributes to tumor cell proliferation and survival. HRS cells of classical Hodgkin lymphoma have a highly abnormal genome, and immune evasion occurs through PD-L1 overexpression.

6. Symptoms

Cardiac malignancies

Mediastinal malignancies

Pleural malignancies

7. Signs

Signs of cardiac malignancy

On physical examination, diminished heart sounds or, in the presence of pericardial effusion, a pericardial friction rub is heard on auscultation. In cardiac tamponade, Beck's triad (hypotension, jugular venous distension, diminished heart sounds) and pulsus paradoxus appear. If the tumor causes valvular lesions, a heart murmur is heard. In right atrial angiosarcoma, signs of right heart failure (jugular venous distension, hepatomegaly, lower extremity edema) due to a mass filling the heart are observed.

Signs of mediastinal tumors

Signs of SVC syndrome include swelling of the face, neck, and upper limbs, flushing of the head and neck skin, jugular venous distension, and distended superficial veins of the upper chest. In lymphoma, cervical, axillary, and inguinal lymphadenopathy may be present. Tumors invading the mediastinum can cause recurrent laryngeal nerve involvement or Horner syndrome.

Signs of pleural tumors

With pleural effusion, dullness to percussion and decreased breath sounds are observed on the affected side. With severe pleural thickening, a 'pleural peel' is seen on imaging, and respiratory function declines due to chest wall restriction. Systemic findings such as fever, sweating, and weight loss may accompany.

8. Screening

Because tumors within the C38 category have very low incidence, standard screening of the general population is not recommended.

Regular imaging follow-up is recommended in the following high-risk groups:

9. Diagnosis

Imaging diagnosis

Chest CT (contrast-enhanced) is the basic test for evaluating mediastinal and pleural tumors, assessing tumor location, size, and invasion of surrounding structures. Cardiac MRI is superior to CT for characterizing cardiac tumor tissue, assessing myocardial invasion, and evaluating operability. Contrast-enhanced MRI in particular reflects the vascular tissue characteristics of angiosarcoma well. Echocardiography is sensitive for detecting intracardiac masses and evaluates the amount and hemodynamic impact of pericardial effusion. PET-CT is useful for assessing malignancy and systemic staging.

Tissue diagnosis

Mediastinal tumors: tissue is obtained by CT-guided percutaneous needle biopsy, mediastinoscopy, video-assisted thoracoscopic surgery (VATS), anterior mediastinotomy, and so on. Pleural tumors: thoracoscopic pleural biopsy (best), CT-guided needle biopsy. Cardiac tumors: pathologic examination of tissue resected at surgery is the main diagnostic method, and percutaneous biopsy is performed only in limited cases because of its high risk. Pericardiocentesis is used for cytology of pericardial effusion fluid.

Pathology

Histologic classification by immunohistochemistry: angiosarcoma (CD31, CD34, ERG positive), lymphoma (CD20, CD30, BCL6, etc.), pleural mesothelioma (calretinin, CK5/6, WT1 positive, CEA negative). In mediastinal lymphoma, the Ki-67 proliferation index and rearrangement FISH testing (MYC, BCL2, BCL6) are important for prognosis and treatment decisions. PD-L1 expression testing is needed to assess eligibility for immunotherapy.

10. Treatment

Primary cardiac malignancies

When resectable, complete surgical resection is the first-line treatment, but complete resection is often difficult due to the anatomic location and relationship to intracardiac structures. In angiosarcoma, paclitaxel alone or anthracycline-based combination chemotherapy is used. Adjuvant radiotherapy is sometimes given after surgery. Recently, targeted therapies such as VEGFR inhibitors (sorafenib, sunitinib) have been studied in angiosarcoma, and heart transplantation has been reported in some selected patients.

Mediastinal malignancies (lymphoma)

Standard treatment for primary mediastinal large B-cell lymphoma (PMBCL) is R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone) or the DA-EPOCH-R regimen, with response assessed by PET-CT after treatment. If residual disease is present, additional mediastinal radiotherapy is considered. Pembrolizumab has received FDA approval for relapsed/refractory PMBCL. Classical Hodgkin lymphoma is based on ABVD or BEACOPP chemotherapy, and in advanced stages an anti-CD30 antibody-drug conjugate (brentuximab vedotin) is added.

Pleural malignancies

Treatment of malignant pleural tumors differs by histologic type. For metastatic pleural tumors, treatment of the primary tumor takes priority, and pleural drainage and pleurodesis are performed for symptom relief. For primary pleural sarcoma, adjuvant therapy is considered after surgical resection.

11. Prognosis

The prognosis of malignancies within the C38 category varies greatly with histologic type and stage at diagnosis.

Primary cardiac malignancies generally have a poor prognosis. In angiosarcoma, median survival is 6–12 months after diagnosis, and recurrence is frequent even after complete resection. Because of their intracardiac origin, early detection is difficult and complete surgical resection is often technically difficult, so the overall prognosis is poor. The 5-year survival rate is mostly less than 10–20%.

Mediastinal lymphoma has a relatively favorable prognosis. Primary mediastinal large B-cell lymphoma has an excellent 3-year event-free survival of about 87% with DA-EPOCH-R treatment. Hodgkin lymphoma has very good treatment outcomes, with a 5-year survival rate of 80–90%.

The prognosis of pleural malignancies varies by histologic type, and metastatic pleural tumors follow the prognosis of the primary tumor. Malignant pleural mesothelioma has a poor median survival of 12–21 months, but this is improving with combination immunotherapy.

12. Prevention


13. References